A study estimated the number of US Alzheimer's disease cases will double by 2060, and author Ron Brookmeyer said the findings highlight the need for ways to better identify people who will develop the disease and for new interventions to slow or stop disease progression. The research, published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association, found that about 5.7 million people will have mild cognitive impairment and 9.3 million will have Alzheimer's disease by 2060.
Researchers found that patients with newly diagnosed type 2 diabetes who achieve early and maintained A1C control between 6.5% and 7% were at a reduced likelihood of experiencing a cardiovascular event than those who maintain an aggressive or poor glycemic control. The findings in Current Medical Research and Opinion, based on data from 11,426 patients, also revealed that aggressive glucose control increases macrovascular risk among those with a longer diabetes duration and those with poor glycemic control at the time of the intensive therapy initiation.
Data showed 88.4% of men with Parkinson's disease had a caregiver, compared with 79.4% of women, and caregiver strain was greater for those caring for men, according to a study in Neurology. Women were less likely than men to have a caregiver accompany them for a baseline medical visit and went to using a paid caregiver at a faster rate than men.
The use of artificial intelligence can increase the accuracy and sensitivity of adenoma detection during colonoscopy, even for small lesions, Dr. William Karnes of the University of California at Irvine told the World Congress of Gastroenterology at ACG 2017. Dr. Yuichi Mori of Showa University in Shinagawa-ku, Japan, reported at United European Gastroenterology Week 2017 that the EndoBRAIN computer-aided system yielded an automatic diagnosis of a lesion during colonoscopy and had a high polyp detection rate.
The FDA granted full approval to Roche Holding unit Genentech's Avastin, or bevacizumab, which is intended to treat glioblastoma in adult patients whose disease progressed after prior treatment. The company previously received provisional approval under the agency's accelerated approval provision.
The National Institute for Health and Care Excellence recommended against National Health Service and Cancer Drugs Fund use of Novartis' Rydapt, or midostaurin, as a treatment for patients with FLT3-mutated acute myeloid leukemia. The regulator did not consider the drug cost-effective and was uncertain of Rydapt's effectiveness in people older than age 60 because a clinical trial did not include that age group.
Researchers and nursing homes are using an NIH grant to develop an advance care planning program for patients with Alzheimer's disease and other dementias that can be integrated into the homes' regular workflows. The project aims to create decision-making supports and have nursing home staff work with residents and their families on care goals and values.
House Republicans are looking at delaying the Affordable Care Act's tax on health insurance for only some markets next year, leaving the tax in place for small businesses and potentially private Medicaid plans. The tax would be suspended for all markets in 2019 if the measure is included in a year-end bill that also might delay the medical device tax, relax health savings account restrictions and put the Cadillac tax on hold.
A pilot program for OurNotes, an initiative targeting patient-provider collaboration in writing clinical notes and care plans within a shared EHR, will begin in the spring at Beth Israel Deaconess Medical Center, the University of Colorado, the University of Washington and Dartmouth-Hitchcock Medical Center. Beth Israel, which uses its own EHR system, will aid in organizing and standardizing efforts with the other sites, which use Epic systems, said Dr. Matthew Germak of Beth Israel.
Register by Monday, Dec. 18, and save up to $400 off your AACR-SNMMI Joint Conference on State-of-the-Art Molecular Imaging in Cancer Biology and Therapy registration. You'll connect with the profession's foremost experts on topics including emerging advances in imaging technologies; super-resolution imaging of cancer biology and metastasis; novel ligands and target identification; optics in the oncology surgical suite; and more! Advance registration ends Dec. 18. Register today.
The news summaries appearing in SNMMI SmartBrief are based on original information from multiple internet sources and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The items above are not selected or reviewed by SNMMI prior to publication. Questions and comments may be directed to SmartBrief at email@example.com.